English  |  正體中文  |  简体中文  |  Items with full text/Total items : 58325/91879 (63%)
Visitors : 1748      Online Users : 131
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/109463

    Title: No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment
    Authors: Hung, Tsung-Hsing;Tsai, Chen-Chi;Tseng, Chih-Wei;Tseng, Kuo-Chih;Hsieh, Yu-Hsi;Tsai, Chih-Chun
    Keywords: esophageal variceal bleeding;renal function impairment;somatostatin;terlipressin
    Date: 2016-11
    Issue Date: 2017-02-21 02:10:31 (UTC+8)
    Abstract: Objective
    To study the differences in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding (EVB) and renal functional impairment (RFI).

    The National Health Insurance Database, part of the Taiwan National Health Insurance Program, was used to enroll cirrhotic patients who had received endoscopic variceal ligation plus somatostatin or terlipressin for EVB and who were hospitalized between 1 January 2007 and 31 December 2010. The differences in mortality between the two vasoactive agents were compared and the risk factors for 30-day mortality because of EVB were identified.

    A total of 2324 cirrhotic patients with EVB were enrolled. The 30-day mortality data showed no significant differences between the somatostatin and the terlipressin groups (P=0.232). The risk of 30-day mortality was significantly higher in male patients [hazard ratio (HR): 1.50, P=0.002] and patients with hepatic encephalopathy (HR: 1.82, P<0.001), ascites (HR: 1.32, P=0.008), bacterial infections (HR: 2.10, P<0.001), hepatocellular carcinoma (HR: 2.09, P<0.001), and RFI (HR: 3.89, P<0.001). A subgroup analysis of cirrhotic patients with RFI was carried out. The overall 30-day mortality was higher in patients treated with somatostatin than in those treated with terlipressin (52.6 vs. 42.3%), but the difference failed to reach significance (adjust HR: 1.49, 95% confidence interval: 0.94–2.37, P=0.091).

    RFI was the most important risk factor for 30-day mortality in EVB patients. Terlipressin and somatostatin had similar effects on 30-day mortality in cirrhotic patients with EVB and RFI.
    Relation: European Journal of Gastroenterology & Hepatology 28(11), p.1275–1279
    DOI: 10.1097/MEG.0000000000000703
    Appears in Collections:[Graduate Institute & Department of Mathematics] Journal Article

    Files in This Item:

    File Description SizeFormat
    No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment.pdf288KbAdobe PDF0View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback